Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Deyuan Pharmaceutical CoBJSE:920735 97 EBITDA Margin % is 31.55% as of Jun. 2026, which is 23% above its 10-year median of 25.62. GuruFocus rates BJSE:920735 with a GF Score™ of 97/100 and a GF Value™ of ¥29.61 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Jiangsu Deyuan Pharmaceutical Co ranks better than 82.27% on this metric.
Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jiangsu Deyuan Pharmaceutical Co EBITDA Margin % Related Terms
Jiangsu Deyuan Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Deyuan Pharmaceutical Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Deyuan Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Deyuan Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Deyuan Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Deyuan Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) has a EBITDA Margin % of 31.55% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Deyuan Pharmaceutical Co and its competitors. This is 23% above median its historical median of 25.62. Over the past decade, Jiangsu Deyuan Pharmaceutical Co's EBITDA Margin % has ranged from 20.08 to 30.78. According to the industry distribution chart, Jiangsu Deyuan Pharmaceutical Co ranks #170 out of 959 companies in the Drug Manufacturers industry, placing it in the top 17.7%.
Is Jiangsu Deyuan Pharmaceutical Co's EBITDA Margin % too high?
Jiangsu Deyuan Pharmaceutical Co's current EBITDA Margin % of 31.55% is 23% above median its 10-year median of 25.62. Over the past 10 years, this metric has ranged from a low of 20.08 to a high of 30.78. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Jiangsu Deyuan Pharmaceutical Co's value of 31.55% is 165.3% above this industry median. Based on the distribution chart, Jiangsu Deyuan Pharmaceutical Co ranks #170 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Deyuan Pharmaceutical Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Deyuan Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Deyuan Pharmaceutical Co ranks #170 out of 959 companies for EBITDA Margin %. This places Jiangsu Deyuan Pharmaceutical Co in the top 18% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 11.89. Jiangsu Deyuan Pharmaceutical Co's value of 31.55% is 165.3% above this benchmark. Historically, Jiangsu Deyuan Pharmaceutical Co's own EBITDA Margin % has ranged from 20.08 to 30.78 over the past decade. While the company's 10-year median is 25.62 vs. the industry median of 11.89, Jiangsu Deyuan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Deyuan Pharmaceutical Co's current EBITDA Margin % of 31.55% is 165.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Deyuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Deyuan Pharmaceutical Co's current EBITDA Margin % is 31.55%, which is 23% above median its own 10-year median of 25.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Deyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.61, compared to a current price of ¥26.66 — trading 10% below its estimated fair value. The current EBITDA Margin % is 31.55%, which is 23% above median its 10-year median of 25.62 and 165.3% above the Drug Manufacturers industry median of 11.89. Jiangsu Deyuan Pharmaceutical Co's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jiangsu Deyuan Pharmaceutical Co (BJSE:920735), the current EBITDA Margin % is 31.55% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥26.66 is trading 10% below its estimated GF Value™ of ¥29.61.
GuruFocus considers Jiangsu Deyuan Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for BJSE:920735:
EBITDA Margin %: 31.55% (23% above median its 10-year median of 25.62)
GF Value™: ¥29.61 vs. price of ¥26.66 (10% below fair value)
Industry Position: 165.3% above the Drug Manufacturers median (#170 of 959)
No single metric tells the full story. See the BJSE:920735 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920735 has been successfully added to your 
